Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |
---|---|
First Received Date † | August 16, 2001 |
Last Updated Date | June 23, 2005 |
Start Date † | September 1998 |
Current Primary Outcome Measures † | |
Original Primary Outcome Measures † | |
Change History | Complete list of historical versions of study NCT00022958 on ClinicalTrials.gov Archive Site |
Current Secondary Outcome Measures † | |
Original Secondary Outcome Measures † | |
Descriptive Information | |
Brief Title † | Expanded Access Study of Iodine-131 Anti-B1 Antibody |
Official Title † | Expanded Access Study of Iodine-131 Anti-B1 Antibody for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma |
Brief Summary | The primary objective of this study is to make Iodine-131 Anti-B1 Antibody more broadly available to patients. Secondary endpoints of the study will be to obtain additional information on the efficacy and safety of Iodine-131 Anti-B1 Antibody. |
Detailed Description | |
Study Phase | |
Study Type † | Interventional |
Study Design † | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Condition † | Non-Hodgkin's Lymphoma |
Intervention † | Drug: Iodine-131 Anti-B1 Antibody |
Study Arms / Comparison Groups | |
Publications * | |
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|
Recruitment Information | |
Recruitment Status † | Active, not recruiting |
Enrollment † | |
Completion Date | |
Primary Completion Date | |
Eligibility Criteria † | INCLUSION CRITERIA:
EXCLUSION CRITERIA:
|
Gender | Both |
Ages | 18 Years and older |
Accepts Healthy Volunteers | No |
Contacts †† | |
Location Countries † | United States |
Expanded Access Status | |
Administrative Information | |
NCT ID † | NCT00022958 |
Responsible Party | |
Secondary IDs †† | |
Study Sponsor † | Corixa Corporation |
Collaborators †† | GlaxoSmithKline |
Investigators † | |
Information Provided By | Corixa Corporation |
Verification Date | August 2004 |
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |